Pei Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pei Hu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Ji Jiang
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing
6 shared publicationsXia Chen
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing
5 shared publicationsQian Zhao
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing
3 shared publicationsXin Zheng
Clinical Pharmacological Research Centre, Peking Union Medical College Hospital, Beijing, China
3 shared publicationsDongyang Liu
Peking Union Medical College Hospital and Chinese Academy of Medical Sciences
2 shared publicationsAnn Allen
Respiratory Medicines Development Centre, GlaxoSmithKline, Stevenage, Hertfordshire, UK
1 shared publication
Latest Publications
- 1 August 2016
- Published by Elsevier in Clinical Therapeutics
- Vol. 38 (8) , 1869-1879
Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects
- 1 August 2016
- Published by Elsevier in Clinical Therapeutics
- Vol. 38 (8) , 1869-1879
Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects
- Open Access
- 25 February 2016
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 82 (1) , 41-52
Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT‐18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis
Aim: RCT‐18 is a recombinant fusion protein that interferes with the selection and survival of mature B‐lymphocytes by inhibiting B‐lymphocyte stimulator and a proliferation‐inducing ligand.Methods: This single blind, randomized, placebo controlled, clinical pharmacological study explored the short term efficacy and safety of RCT‐18 in 21 rheumatoid arthritis (RA) patients with three different dosing regimens. The pharmacological behaviour of RCT‐18 was also characterized through a six level biomarker cascade approach to identify potential predictors for clinical responses.Results: Nine out of 10 patients (>80%) experienced moderate to good EULAR response at the end of 3 months with once or twice weekly doses of 180 mg RCT‐18, whereas weekly administration of 360 mg RCT‐18 or placebo, however, only resulted in moderate improvement in one patient in each group. Absence of IgM‐type rheumatoid factor reduction, recovery of IgM 2 weeks after drug cessation, lack of decrease in the count of CD27(+) B‐lymphocytes and a DAS28 change from baseline <6 in 4–6 weeks after the treatment initiation may indicate poor clinical response. No anti‐drug antibody of RCT‐18 was detected. The active treatments were well tolerated, although more mild to moderate infections were reported in patients receiving RCT‐18.Conclusion: The study results support further development of RCT‐18 in RA patients and provide important information for future dose selection.
- 25 February 2016
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 82 (1) , 41-52
Open AccessPharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT‐18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis
Aim: RCT‐18 is a recombinant fusion protein that interferes with the selection and survival of mature B‐lymphocytes by inhibiting B‐lymphocyte stimulator and a proliferation‐inducing ligand.Methods: This single blind, randomized, placebo controlled, clinical pharmacological study explored the short term efficacy and safety of RCT‐18 in 21 rheumatoid arthritis (RA) patients with three different dosing regimens. The pharmacological behaviour of RCT‐18 was also characterized through a six level biomarker cascade approach to identify potential predictors for clinical responses.Results: Nine out of 10 patients (>80%) experienced moderate to good EULAR response at the end of 3 months with once or twice weekly doses of 180 mg RCT‐18, whereas weekly administration of 360 mg RCT‐18 or placebo, however, only resulted in moderate improvement in one patient in each group. Absence of IgM‐type rheumatoid factor reduction, recovery of IgM 2 weeks after drug cessation, lack of decrease in the count of CD27(+) B‐lymphocytes and a DAS28 change from baseline <6 in 4–6 weeks after the treatment initiation may indicate poor clinical response. No anti‐drug antibody of RCT‐18 was detected. The active treatments were well tolerated, although more mild to moderate infections were reported in patients receiving RCT‐18.Conclusion: The study results support further development of RCT‐18 in RA patients and provide important information for future dose selection.
- Open Access
- 23 November 2015
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 37 (2) , 276-284
Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration
To evaluate the SimCYP simulator ethnicity-specific population model for predicting the pharmacokinetics of midazolam, a typical CYP3A4/5 substrate, in Chinese after oral administration. The physiologically based pharmacokinetic (PBPK) model for midazolam was developed using a SimCYP population-based simulator incorporating Chinese population demographic, physiological and enzyme data. A clinical trial was conducted in 40 Chinese subjects (the half was females) receiving a single oral dose of 15 mg midazolam. The subjects were separated into 4 groups based on age (20–50, 51–65, 66–75, and above 76 years), and the pharmacokinetics profiles of each age- and gender-group were determined, and the results were used to verify the PBPK model. Following oral administration, the simulated profiles of midazolam plasma concentrations over time in virtual Chinese were in good agreement with the observed profiles, as were AUC and Cmax. Moreover, for subjects of varying ages (20–80 years), the ratios of predicted to observed clearances were between 0.86 and 1.12. The SimCYP PBPK model accurately predicted the pharmacokinetics of midazolam in Chinese from youth to old age. This study may provide novel insight into the prediction of CYP3A4/5-mediated pharmacokinetics in the Chinese population relative to Caucasians and other ethnic groups, which can support the rational design of bridging clinical trials.
- 23 November 2015
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 37 (2) , 276-284
Open AccessEvaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration
To evaluate the SimCYP simulator ethnicity-specific population model for predicting the pharmacokinetics of midazolam, a typical CYP3A4/5 substrate, in Chinese after oral administration. The physiologically based pharmacokinetic (PBPK) model for midazolam was developed using a SimCYP population-based simulator incorporating Chinese population demographic, physiological and enzyme data. A clinical trial was conducted in 40 Chinese subjects (the half was females) receiving a single oral dose of 15 mg midazolam. The subjects were separated into 4 groups based on age (20–50, 51–65, 66–75, and above 76 years), and the pharmacokinetics profiles of each age- and gender-group were determined, and the results were used to verify the PBPK model. Following oral administration, the simulated profiles of midazolam plasma concentrations over time in virtual Chinese were in good agreement with the observed profiles, as were AUC and Cmax. Moreover, for subjects of varying ages (20–80 years), the ratios of predicted to observed clearances were between 0.86 and 1.12. The SimCYP PBPK model accurately predicted the pharmacokinetics of midazolam in Chinese from youth to old age. This study may provide novel insight into the prediction of CYP3A4/5-mediated pharmacokinetics in the Chinese population relative to Caucasians and other ethnic groups, which can support the rational design of bridging clinical trials.
- 1 July 2015
- Published by Elsevier in Clinical Therapeutics
- Vol. 37 (7) , 1483-1492.e1
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects
- 1 July 2015
- Published by Elsevier in Clinical Therapeutics
- Vol. 37 (7) , 1483-1492.e1
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects
- Open Access
- 9 June 2015
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 35 (6) , 586-599
Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
Study Objective: To investigate the pharmacodynamic and pharmacokinetic profiles of fluticasone furoate (FF)/vilanterol (VI) – a fixed‐dose combination of an inhaled corticosteroid (ICS) and a long‐acting β2‐agonist for the treatment of asthma and chronic obstructive pulmonary disease – after single and repeat administration in healthy Chinese subjects.Design: Double‐blind, placebo‐controlled, single‐site, randomized, four‐way crossover study.Setting: The Clinical Pharmacological Research Centre at Peking Union Medical College Hospital [PUMCH]) in Beijing, China.Subjects: Sixteen healthy, nonsmoking Chinese adults.Intervention: Subjects were randomized to receive FF/VI 50/25, 100/25, or 200/25 μg, or placebo once/daily in the morning, delivered by the Ellipta dry powder inhaler, for 7 consecutive days. The subjects then received the other three treatments, with each treatment period separated by a 7‐day washout period.Measurements and Main Results: The co‐primary outcome measures reflected pharmacodynamic responses relating to recognized class effects of the two drug classes: reduced serum cortisol level (ICSs), and increased Fridericia's corrected QT interval (QTcF) and reduced serum potassium level (long‐acting β2‐agonists). Co‐primary pharmacodynamic endpoints were 0–24‐hour weighted mean serum cortisol level on day 7 (cortisol0–24 hr, Day 7), and 0–4‐hour weighted mean and maximum QTcF and weighted mean and minimum serum potassium level on days 1 and 7. Fluticasone furoate and VI plasma concentrations, derived pharmacokinetic parameters, and safety were also assessed. Of the 16 subjects randomized, 15 completed the study. Reductions in cortisol0–24 hour, Day 7 of 15% and 25% were observed with FF/VI 100/25 and 200/25 μg, respectively, versus placebo. Minor increases (< 10 msec) in maximum QTcF on day 7 were seen with FF/VI 50/25 and 100/25 μg but not with 200/25 μg. Slight decreases in serum potassium level were only observed in subjects receiving FF/VI 50/25 μg on day 1 and FF/VI 50/25 and 200/25 μg on day 7. Fluticasone furoate accumulation (day 7 vs day 1) for FF/VI 50/25–200/25 μg ranged from 38 to 54% for maximum observed concentration and 63–71% for area under the concentration‐time curve from 0 to 4 hours. Fluticasone furoate pharmacokinetics were less than dose proportional. The VI pharmacokinetic profiles were similar for all three FF/VI doses. Adverse events were all mild in intensity and were reported by 13 (81%) of the 16 subjects.Conclusion: In healthy Chinese subjects, minimal and non–clinically relevant β‐adrenergic pharmacodynamic effects were observed with FF/VI doses ranging from 50/25 to 200/25 μg. FF dose‐dependent reductions in serum cortisol levels of 15–25% were seen after administration of FF/VI 100/25 and 200/25 μg. FF/VI was safe and well tolerated in these subjects at doses ranging from 50/25 to 200/25 μg.
- 9 June 2015
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 35 (6) , 586-599
Open AccessPharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
Study Objective: To investigate the pharmacodynamic and pharmacokinetic profiles of fluticasone furoate (FF)/vilanterol (VI) – a fixed‐dose combination of an inhaled corticosteroid (ICS) and a long‐acting β2‐agonist for the treatment of asthma and chronic obstructive pulmonary disease – after single and repeat administration in healthy Chinese subjects.Design: Double‐blind, placebo‐controlled, single‐site, randomized, four‐way crossover study.Setting: The Clinical Pharmacological Research Centre at Peking Union Medical College Hospital [PUMCH]) in Beijing, China.Subjects: Sixteen healthy, nonsmoking Chinese adults.Intervention: Subjects were randomized to receive FF/VI 50/25, 100/25, or 200/25 μg, or placebo once/daily in the morning, delivered by the Ellipta dry powder inhaler, for 7 consecutive days. The subjects then received the other three treatments, with each treatment period separated by a 7‐day washout period.Measurements and Main Results: The co‐primary outcome measures reflected pharmacodynamic responses relating to recognized class effects of the two drug classes: reduced serum cortisol level (ICSs), and increased Fridericia's corrected QT interval (QTcF) and reduced serum potassium level (long‐acting β2‐agonists). Co‐primary pharmacodynamic endpoints were 0–24‐hour weighted mean serum cortisol level on day 7 (cortisol0–24 hr, Day 7), and 0–4‐hour weighted mean and maximum QTcF and weighted mean and minimum serum potassium level on days 1 and 7. Fluticasone furoate and VI plasma concentrations, derived pharmacokinetic parameters, and safety were also assessed. Of the 16 subjects randomized, 15 completed the study. Reductions in cortisol0–24 hour, Day 7 of 15% and 25% were observed with FF/VI 100/25 and 200/25 μg, respectively, versus placebo. Minor increases (< 10 msec) in maximum QTcF on day 7 were seen with FF/VI 50/25 and 100/25 μg but not with 200/25 μg. Slight decreases in serum potassium level were only observed in subjects receiving FF/VI 50/25 μg on day 1 and FF/VI 50/25 and 200/25 μg on day 7. Fluticasone furoate accumulation (day 7 vs day 1) for FF/VI 50/25–200/25 μg ranged from 38 to 54% for maximum observed concentration and 63–71% for area under the concentration‐time curve from 0 to 4 hours. Fluticasone furoate pharmacokinetics were less than dose proportional. The VI pharmacokinetic profiles were similar for all three FF/VI doses. Adverse events were all mild in intensity and were reported by 13 (81%) of the 16 subjects.Conclusion: In healthy Chinese subjects, minimal and non–clinically relevant β‐adrenergic pharmacodynamic effects were observed with FF/VI doses ranging from 50/25 to 200/25 μg. FF dose‐dependent reductions in serum cortisol levels of 15–25% were seen after administration of FF/VI 100/25 and 200/25 μg. FF/VI was safe and well tolerated in these subjects at doses ranging from 50/25 to 200/25 μg.
- 21 May 2015
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 71 (7) , 843-850
Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect
Icotinib is a potent and selective inhibitor of epidermal growth factor receptors (EGFR) approved to treat non-small cell lung cancer (NSCLC). However, its high variability may impede its application. The objectives of this analysis were to assess plasma pharmacokinetics and identify covariates that may explain variability in icotinib absorption and/or disposition following single dose of icotinib in healthy volunteers.
- 21 May 2015
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 71 (7) , 843-850
Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect
Icotinib is a potent and selective inhibitor of epidermal growth factor receptors (EGFR) approved to treat non-small cell lung cancer (NSCLC). However, its high variability may impede its application. The objectives of this analysis were to assess plasma pharmacokinetics and identify covariates that may explain variability in icotinib absorption and/or disposition following single dose of icotinib in healthy volunteers.
- 18 March 2015
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 11 (6) , 857-868
Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug–drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling
(2015). Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug–drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling. Expert Opinion on Drug Metabolism & Toxicology: Vol. 11, No. 6, pp. 857-868.
- 18 March 2015
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 11 (6) , 857-868
Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug–drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling
(2015). Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug–drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling. Expert Opinion on Drug Metabolism & Toxicology: Vol. 11, No. 6, pp. 857-868.